Affimed Announces Presentations at the AACR Annual Meeting 2021
March 10 2021 - 5:22PM
- AFM24 preclinical in vivo data will be presented as a
poster
- Data on AFM13 in combination with adoptive NK cells will be
presented during a Major Symposium
Heidelberg, Germany, March 10, 2021 – Affimed
N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company
committed to giving patients back their innate ability to fight
cancer, announced today that preclinical anti-tumor efficacy in
vivo data from its innate cell engager (ICE®) AFM24 have been
accepted for e-poster presentation at the American Association for
Cancer Research (AACR) Virtual Annual Meeting I, being held on
April 10-15.
In addition, early data from a Phase 1 study evaluating AFM13
preloaded CAR-like cord blood-derived NK cells followed by weekly
AFM13 monotherapy in patients with recurrent or refractory
CD30-expressing lymphomas at The University of Texas MD Anderson
Cancer Center will be presented by Katy Rezvani during a Major
Symposium on April 13th.
Poster details:
Title: AFM24 is a novel, highly potent,
tetravalent bispecific EGFR/CD16A-targeting Innate Cell Engager
(ICE®) designed for the treatment of EGFR-positive malignancies
Abstract: 1881
Authors: Jens Pahl, Gabriele Hintzen, Uwe
Reusch, Torsten Haneke, Christian Breunig, Sheena Pinto, Cassandra
Choe-Juliak, Andreas Harstrick, Wolfgang Fischer, Arndt
Schottelius, Joachim Koch, Erich Rajkovic
Poster Release: The e-poster website will be
launched on April 10, 2021. All e-posters will be available for
browsing on this date. The poster will also be available on the
Company’s website - www.affimed.com
Major Symposium Details:
Session Title: Engineering and Modulating
Natural Killer (NK) Cells for Cancer Immunotherapy
Session Number: SY30
Talk: CAR-NK, a Drive to the Future of Cell
Therapy
Speaker: Katy Rezvani, MD, PhD, Sally Copper
Murray Endowed Chair in Cancer Research Professor of Medicine,
Chief, Section of Cellular Therapy, Director for Translational
Research Medical Director, SCT Laboratory and the GMP Laboratory,
Department of Stem Cell Transplantation and Cellular Therapy, MD
Anderson
Moderated 30-minute Panel Session for Q&A
Date: Tuesday, April 13, 1:30-2:00 pm ET
More details about the programs for the AACR Virtual Annual
Meetings are available online at www.aacr.org.
About AFM13
AFM13 is a first-in-class innate cell engager (ICE®) that
uniquely activates the innate immune system to destroy
CD30-positive hematologic tumors. AFM13 induces specific and
selective killing of CD30-positive tumor cells, leveraging the
power of the innate immune system by engaging and activating
natural killer (NK) cells and macrophages. AFM13 is Affimed’s most
advanced ICE® clinical program and is currently being evaluated as
a monotherapy in a registration-directed trial in patients with
relapsed/refractory peripheral T-cell lymphoma or transformed
mycosis fungoides (REDIRECT). The study is actively recruiting, and
additional details can be found at www.clinicaltrials.gov using the
identifier NCT04101331.
In addition, Affimed is studying AFM13 in combination with cord
blood-derived allogeneic NK cells in patients with recurrent or
refractory CD30-positive Hodgkin or non-Hodgkin lymphomas. The
investigator-sponsored Phase 1 study, conducted at the MD Anderson
Cancer Center in Houston, is administering a CAR-like, stable
complex of AFM13 pre-loaded cord blood-derived allogeneic NK cells.
The study can be found at www.clinicaltrials.gov using the
identifier NCT04074746.
About AFM24
AFM24 is a tetravalent, bispecific innate cell engager (ICE®)
that activates the innate immune system by binding to CD16A on
innate immune cells and EGFR, a protein widely expressed on solid
tumors, to kill cancer cells. Generated by Affimed’s
fit-for-purpose ROCK® platform, AFM24 represents a distinctive
mechanism of action that uses EGFR as a docking site to engage
innate immune cells for tumor cell killing through
antibody-dependent cellular cytotoxicity and antibody-dependent
cellular phagocytosis.
Affimed is evaluating AFM24 as a monotherapy for patients with
advanced EGFR-expressing solid malignancies whose disease has
progressed after treatment with previous anticancer therapies.
AFM24-101 is a first-in-human Phase 1/2a open-label,
non-randomized, multi-center, multiple ascending dose escalation
and expansion study and can be found at www.clinicaltrials.gov
using the identifier NCT04259450. In addition, Affimed is planning
to initiate further studies evaluating AFM24 in combination with
adoptive NK cell transfer and in combination with atezolizumab.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology
company committed to give patients back their innate ability to
fight cancer by actualizing the untapped potential of the innate
immune system. The company’s proprietary ROCK® platform enables a
tumor-targeted approach to recognize and kill a range of
hematologic and solid tumors, enabling a broad pipeline of
wholly-owned and partnered single agent and combination therapy
programs. The ROCK® platform predictably generates customized
innate cell engager (ICE®) molecules, which use patients’ immune
cells to destroy tumor cells. This innovative approach enabled
Affimed to become the first company with a clinical-stage ICE®.
Headquartered in Heidelberg, Germany, with offices in New York, NY,
Affimed is led by an experienced team of biotechnology and
pharmaceutical leaders united by a bold vision to stop cancer from
ever derailing patients’ lives. For more about the company’s
people, pipeline and partners, please visit: www.affimed.com.
Investor Relations Contact
Alexander FudukidisHead of Investor RelationsE-Mail:
a.fudukidis@affimed.com Tel.: +1 (917) 436-8102
Media Contact
Mary Beth Sandin Head of Marketing and CommunicationsE-Mail:
m.sandin@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024